Reumatologia clinica最新文献_第10页

Effect of Plasminogen Activator Inhibitor-1 on extracellular matrix homeostasis in scaffold-free spheroids from human chondrocytes 纤溶酶原激活物抑制剂-1对人软骨细胞无支架球体细胞外基质稳态的影响

Reumatologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.reumae.2025.501815

Carlos Suarez-Ahedo , Carlos Martinez-Armenta , Laura E. Martínez-Gómez , Oswaldo González-Mendoza , María de Jesús Hernández Rocha , Gabriela A. Martínez-Nava , Carlos Pineda , Alberto López-Reyes

Introduction

New trends in osteoarthritis research focus on the use of biological therapy; in this context, the use of Plasminogen Activator Inhibitor-1 (PAI-1) is considered a potential therapeutic strategy to prevent extracellular matrix (ECM) degradation in osteoarthritis (OA) management. However, in vitro studies have not demonstrated its effect on the expression of ECM homeostasis-related genes.

Methods

Human OA cartilage-derived chondrocytes were used to generate scaffold-free spheroids under hypoxia conditions. The spheroids were exposed to PAI-1 for 24 h, and cell viability was measured. Then qRT-PCR was used to analyze the expression of ECM components and degradative enzymes, including COL2A1, SOX9, ACAN, COL1A1, MMP3, MMP9, MMP13, ADAMTS4, ADAMTS5, TIMP1, TIMP2, TIMP3, uPA and tPA.

Results

PAI-1 treatment consistently maintained cell viability and chondrocyte spheroid integrity. At the 50 ng/mL concentration, PAI-1 increased the gene expression of COL2A1 and reduced SOX9, ACAN, MMP3, MMP9, TIMP2, and tPA. Moreover, the functional COL2A1/COL1A1 ratio was significantly increased in PAI-1-treated spheroids.

Conclusion

Our results suggest that PAI-1 treatment exerts a complex and multifaceted influence on spheroids’ ECM. While it supports matrix integrity by reducing the gene expression of ECM remodeling enzymes, such as MMPs and ADAMTS5, it also induces unfavorable changes in chondrogenesis-related marker genes, such as SOX9 and ACAN. These findings indicate that the cellular response to PAI-1 is not unidirectional, warranting further investigation to understand its precise biological implications.

骨关节炎研究的新趋势是生物疗法的应用；在这种情况下，使用纤溶酶原激活物抑制剂-1 （PAI-1）被认为是防止骨关节炎（OA）治疗中细胞外基质（ECM）降解的潜在治疗策略。然而，体外研究尚未证实其对ECM稳态相关基因表达的影响。方法利用人OA软骨源性软骨细胞在缺氧条件下生成无支架球体。将球体暴露于PAI-1 24 h，测定细胞活力。然后用qRT-PCR分析ECM组分和降解酶COL2A1、SOX9、ACAN、COL1A1、MMP3、MMP9、MMP13、ADAMTS4、ADAMTS5、TIMP1、TIMP2、TIMP3、uPA和tPA的表达情况。结果spai -1治疗可持续维持细胞活力和软骨细胞球体完整性。在50 ng/mL浓度下，PAI-1增加COL2A1基因的表达，降低SOX9、ACAN、MMP3、MMP9、TIMP2和tPA的表达。此外，在pai -1处理的球体中，COL2A1/COL1A1的功能比值显著增加。结论PAI-1治疗对球体的ECM具有复杂和多方面的影响。虽然它通过降低ECM重塑酶（如MMPs和ADAMTS5）的基因表达来支持基质完整性，但它也会诱导软骨形成相关标记基因（如SOX9和ACAN）的不利变化。这些发现表明，细胞对PAI-1的反应不是单向的，需要进一步研究以了解其确切的生物学意义。

{"title":"Effect of Plasminogen Activator Inhibitor-1 on extracellular matrix homeostasis in scaffold-free spheroids from human chondrocytes","authors":"Carlos Suarez-Ahedo , Carlos Martinez-Armenta , Laura E. Martínez-Gómez , Oswaldo González-Mendoza , María de Jesús Hernández Rocha , Gabriela A. Martínez-Nava , Carlos Pineda , Alberto López-Reyes","doi":"10.1016/j.reumae.2025.501815","DOIUrl":"10.1016/j.reumae.2025.501815","url":null,"abstract":"<div><h3>Introduction</h3><div>New trends in osteoarthritis research focus on the use of biological therapy; in this context, the use of Plasminogen Activator Inhibitor-1 (PAI-1) is considered a potential therapeutic strategy to prevent extracellular matrix (ECM) degradation in osteoarthritis (OA) management. However, <em>in vitro</em> studies have not demonstrated its effect on the expression of ECM homeostasis-related genes.</div></div><div><h3>Methods</h3><div>Human OA cartilage-derived chondrocytes were used to generate scaffold-free spheroids under hypoxia conditions. The spheroids were exposed to PAI-1 for 24h, and cell viability was measured. Then qRT-PCR was used to analyze the expression of ECM components and degradative enzymes, including <em>COL2A1</em>, <em>SOX9</em>, <em>ACAN</em>, <em>COL1A1</em>, <em>MMP3</em>, <em>MMP9</em>, <em>MMP13</em>, <em>ADAMTS4</em>, <em>ADAMTS5</em>, <em>TIMP1</em>, <em>TIMP2</em>, <em>TIMP3</em>, <em>uPA</em> and <em>tPA</em>.</div></div><div><h3>Results</h3><div>PAI-1 treatment consistently maintained cell viability and chondrocyte spheroid integrity. At the 50ng/mL concentration, PAI-1 increased the gene expression of <em>COL2A1</em> and reduced <em>SOX9</em>, <em>ACAN</em>, <em>MMP3</em>, <em>MMP9</em>, <em>TIMP2</em>, and <em>tPA</em>. Moreover, the functional COL2A1/COL1A1 ratio was significantly increased in PAI-1-treated spheroids.</div></div><div><h3>Conclusion</h3><div>Our results suggest that PAI-1 treatment exerts a complex and multifaceted influence on spheroids’ ECM. While it supports matrix integrity by reducing the gene expression of ECM remodeling enzymes, such as MMPs and ADAMTS5, it also induces unfavorable changes in chondrogenesis-related marker genes, such as <em>SOX9</em> and <em>ACAN</em>. These findings indicate that the cellular response to PAI-1 is not unidirectional, warranting further investigation to understand its precise biological implications.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 3","pages":"Article 501815"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare C1q deficiency presenting as pediatric SLE: A case study of two consanguineous siblings 罕见的C1q缺乏表现为小儿SLE：两个近亲兄弟姐妹的病例研究

Reumatologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.reumae.2025.501843

Kerem Parlar , Berkay Aktaş , Sena Ladin Sicakyüz , Sezgin Şahin , Özgür Kasapçopur , Serdal Uğurlu

C1q deficiency is a rare autosomal recessive genetic condition characterized by mutations in genes C1qA, C1qB, or C1qC which can cause a SLE-like disease. Here, we report the cases of two siblings with C1q deficiency, both of whom had homozygous mutations in the C1QA gene. Both of our patients had NP involvement, and the brother had chilblain lesions. Diagnosis of C1q deficiency was delayed, highlighting the importance of clinical suspicion and genetic testing. This is especially crucial in cases with atypical presentations of SLE and a family history of consanguinity.

C1q缺乏症是一种罕见的常染色体隐性遗传病，其特征是基因C1qA、C1qB或C1qC突变，可导致sle样疾病。在这里，我们报告了两个患有C1q缺乏症的兄弟姐妹，他们都有C1QA基因的纯合突变。我们的两个病人都有NP受累，兄弟有冻疮病变。C1q缺乏症的诊断被推迟，凸显了临床怀疑和基因检测的重要性。这在SLE的非典型表现和有家族血缘史的病例中尤为重要。

引用次数: 0

Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry 免疫介导性疾病患者生物和合成靶向治疗的安全性：来自BIOBADAGUAY注册的数据

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.101798

Paloma de Abreu , Sonia Cabrera , Darwin Cordovilla , Lourdes Román , Cristina Brunengo , Patricia Melgarejo , Macarena Soto , Vannia Valinotti , Angelica Amarilla , Belem Acevedo , Alexis Pineda , Evelyn Leiva , Paola Pusineri , Sandra Consani , Mariela Zarza , Clyde Parodi , Zoilo Morel , Roger Rolón , Paola Jara , Raquel Aranda , Rosario Jurado

Objective

To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).

Methods

BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.ser.es. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).

Results

1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.

Conclusions

This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.

目的：分析生物（DMARDs-b）和合成靶向治疗（DMARDs-sd）在BIOBADAGUAY登记（巴拉圭-乌拉圭不良事件登记（ae）在炎症性风湿病患者中的安全性）。方法：BIOBADAGUAY是一个前瞻性评价FAME-b和FAME-sd的疗效和安全性的注册表。完整的方法可在https://biobadaguay.ser.es上找到。本研究使用了与治疗安全性相关的变量。AA的发病率以每1000患者年的发病率（IR）计算，发病率比（IRR）采用95%置信区间（CI）和泊松回归。结果：共分析1104例AA患者（女性73.3%），1366例，以轻度为主（87.2%）。ae的总发生率为251.75 / 1000患者年。感染是最常见的（55.0%），发病率为138.4 / 1000患者年。类风湿关节炎和皮质类固醇的使用与更多的整体不良事件相关，而抗tnf与更少的不良事件相关。结论：这项来自BIOBADAGUAY注册的研究为炎症性风湿病患者队列中的DMARD-b， sd的安全性提供了有价值的数据。以感染为最常见不良事件的轻微不良事件发生率占主导地位，强调了对这一人群进行严格和持续监测的必要性。

{"title":"Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry","authors":"Paloma de Abreu , Sonia Cabrera , Darwin Cordovilla , Lourdes Román , Cristina Brunengo , Patricia Melgarejo , Macarena Soto , Vannia Valinotti , Angelica Amarilla , Belem Acevedo , Alexis Pineda , Evelyn Leiva , Paola Pusineri , Sandra Consani , Mariela Zarza , Clyde Parodi , Zoilo Morel , Roger Rolón , Paola Jara , Raquel Aranda , Rosario Jurado","doi":"10.1016/j.reumae.2025.101798","DOIUrl":"10.1016/j.reumae.2025.101798","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).</div></div><div><h3>Methods</h3><div>BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at <span><span>https://biobadaguay.ser.es</span><svg><path></path></svg></span>. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).</div></div><div><h3>Results</h3><div>1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.</div></div><div><h3>Conclusions</h3><div>This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 101798"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatological diseases in patients with autoimmune hepatitis in a fourth level hospital in Bogotá between 2013 and 2023 2013年至2023年波哥大一家四级医院<e:1>自身免疫性肝炎患者的风湿病

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.501812

Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra

Introduction

Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10 years in a fourth-level hospital in Bogota, Colombia.

Materials and methods

Analytical, observational, cross-sectional study in a single center that included patients over 18 years of age of both sexes with a diagnosis of AIH by simplified score ≥7 points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia between January 2013 and December 2023.

Results

A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.

Conclusion

The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.

自身免疫性肝炎（AIH）是一种全球低患病率的慢性炎症性肝病。该实体与风湿病的共存已在多项研究中进行了评估，并且是高度可变的。本研究的目的是确定在哥伦比亚波哥大一家四级医院治疗10年的成人中风湿性疾病和自身免疫性肝炎共存的频率。材料和方法：在单中心进行分析性、观察性、横断面研究，纳入年龄在18岁以上、简化评分≥7分诊断为AIH的患者，病史于2013年1月至2023年12月在哥伦比亚波哥大的Fundacion Santa Fe de Bogota登记。结果：66例患者符合纳入标准。36.4%的患者伴有自身免疫性疾病，其中Sjögren综合征、系统性红斑狼疮和自身免疫性甲状腺疾病最为常见。结论：在研究的队列中，自身免疫性肝炎与风湿性疾病在成人患者中共存的频率为36.4%，这与全球已报道的14%至44%的患病率范围一致。

{"title":"Rheumatological diseases in patients with autoimmune hepatitis in a fourth level hospital in Bogotá between 2013 and 2023","authors":"Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra","doi":"10.1016/j.reumae.2025.501812","DOIUrl":"10.1016/j.reumae.2025.501812","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10 years in a fourth-level hospital in Bogota, Colombia.</div></div><div><h3>Materials and methods</h3><div>Analytical, observational, cross-sectional study in a single center that included patients over 18 years of age of both sexes with a diagnosis of AIH by simplified score ≥7 points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia between January 2013 and December 2023.</div></div><div><h3>Results</h3><div>A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.</div></div><div><h3>Conclusion</h3><div>The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501812"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the psychometric properties of the Functional Ability Scale in children with juvenile idiopathic arthritis 青少年特发性关节炎患儿功能能力量表心理测量特征的评价

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.101802

Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu

Background and objective

Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.

The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).

Material and methods

Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.

Results

A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].

Conclusions

The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.

背景与目的青少年特发性关节炎（JIA）对身体功能有广泛的影响，因此功能容量（FC）是该人群的主要预后指标之一。FC可以通过自我参照问卷和功能能力量表（CAPFUN）等观察性测试来评估。这个量表的心理测量特性还没有经过测试。本研究的目的是根据基于共识的健康测量工具选择标准（COSMIN）评估JIA儿童CAPFUN的心理测量特性。材料与方法：对称性能测量研究。这些儿童在2018年1月至2019年11月期间被录取。纳入标准：年龄6 - 16岁，JIA诊断，完整的物理治疗评估，包括：CAPFUN量表、儿童健康评估问卷（C-HAQ）、患者自我感知功能能力视觉数值量表（VNSFC）、全球变化评定量表（GROC）和Steinbrocker量表。停止随访的受试者被排除在外。评估的心理测量特性包括：信度、构念效度、反应性和可解释性。结果共对114例患儿进行分析。内部一致性是可以接受的，Cronbach alpha为0.93。重测信度一致性高，类内相关系数为0.999 （95% CI: 0.998-0.999）。在结构效度方面，探索性因子分析产生了可接受的结果，证明了该工具的可靠性。所有的相关系数都很强，所有预定的假设都得到了验证。最小临床重要差异为0.04。[auc 0.90 (95% ci: 0.83-0.91)]。结论对CAPFUN的心理测量特性的评价是令人满意的，在信度、构念效度、反应性和可解释性方面表现出可接受的值。基于这些结果，无论在临床实践还是研究背景下，该工具都可以有效评估JIA患儿的FC。

{"title":"Evaluation of the psychometric properties of the Functional Ability Scale in children with juvenile idiopathic arthritis","authors":"Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu","doi":"10.1016/j.reumae.2025.101802","DOIUrl":"10.1016/j.reumae.2025.101802","url":null,"abstract":"<div><h3>Background and objective</h3><div>Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.</div><div>The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).</div></div><div><h3>Material and methods</h3><div>Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.</div></div><div><h3>Results</h3><div>A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].</div></div><div><h3>Conclusions</h3><div>The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 101802"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of performance of the Still Activity Score for assessment of Adult-onset Still's Disease: Comparative study with Systemic Feature Score and Modified Pouchot-Activity Score Still活动评分在成人发病Still病评估中的应用：与系统特征评分和改良袋活动评分的比较研究

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.501814

Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş

Backgrounds

Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).

Aims

In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.

Method

69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.

Results

Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA < 6 and PhGA ≥ 6, but mPoS and SFS scores were higher in the PhGA ≥ 6 group (p = 0.053, p = 0.001, p = 0.007, respectively). There was a significant correlation between mPoS and PhGA (p = 0.018).

Conclusion

This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.

成人发病的斯蒂尔氏病（AOSD）是一种全身性炎症性疾病。没有明确的AOSD活动指标。目前使用的两种疾病活动度评分是改良袋chot活动评分（mPoS）和系统特征评分（SFS）。最近引入了另一个评分系统，称为静止活动评分（SAS）。在这项单中心横断面研究中，我们的目的是比较SAS与mPoS和SFS的性能，这两种方法长期以来一直用于测量AOSD患者的疾病活动性。方法筛选2010年至2020年期间在安卡拉大学医学院就诊的69例18岁及以上的AOSD患者。我们比较了SAS、SFS和mPoS与AOSD患者的医师整体评估（PhGA）。结果69例AOSD患者中，45例符合Yamaguchi标准。结果显示，PhGA和lt患者的SAS无显著差异；PhGA≥6组和PhGA≥6组的mPoS和SFS评分较高（p = 0.053, p = 0.001, p = 0.007）。mPoS与PhGA有显著相关性（p = 0.018）。结论本研究首次评价了用于AOSD患者的SAS评分。SAS是用户友好的，但在评估AOSD的疾病活动性方面可能不如mPoS和SFS敏感。

{"title":"Evaluation of performance of the Still Activity Score for assessment of Adult-onset Still's Disease: Comparative study with Systemic Feature Score and Modified Pouchot-Activity Score","authors":"Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş","doi":"10.1016/j.reumae.2025.501814","DOIUrl":"10.1016/j.reumae.2025.501814","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).</div></div><div><h3>Aims</h3><div>In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.</div></div><div><h3>Method</h3><div>69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.</div></div><div><h3>Results</h3><div>Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA<6 and PhGA≥6, but mPoS and SFS scores were higher in the PhGA≥6 group (<em>p</em>  =0.001, <em>p</em>  =0.018).</div></div><div><h3>Conclusion</h3><div>This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501814"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nontraumatic terminal ileal perforation in a patient with resistant palindromic rheumatism treated with sarilumab: A case report 非外伤性回肠终末穿孔在病人的顽固性复发性风湿病治疗沙伐单抗：一个病例报告。

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.501811

Anastasia Mocritcaia , Rocío García-Pérez , Beatriz Frade , Raimon Sanmartí

Intestinal perforation, a rare complication of interleukin (IL)-6 therapy for immune-mediated diseases (mainly rheumatoid arthritis), typically manifests in the lower gastrointestinal tract, often in association with prior history of diverticulitis. Patients may present with acute abdominal pain and suspicion for this complication should remain high even in the absence of elevated C-reactive protein. We describe a 69-year-old female patient with a history of resistant seropositive palindromic rheumatism treated with sarilumab who developed a nontraumatic terminal ileal perforation.

肠穿孔是白细胞介素(IL)-6治疗免疫介导性疾病（主要是类风湿性关节炎）的一种罕见并发症，通常表现在下胃肠道，通常与憩室炎病史相关。患者可能出现急性腹痛，即使没有c反应蛋白升高，对这种并发症的怀疑也应该很高。我们描述了一位69岁的女性患者，她有耐药血清阳性的回复性风湿病史，接受了沙伐单抗治疗，并发了非创伤性回肠末端穿孔。

引用次数: 0

Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic 墨西哥混血类风湿性关节炎患者的合并症：一项523例预防性心脏风湿病临床患者的横断面研究

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.501813

Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza

Objective

The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.

Methods

We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.

Results

523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.

Conclusion

Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.

目的：本研究的目的是确定墨西哥混血类风湿性关节炎（RA）患者队列中心血管危险因素和合并症的患病率。方法：我们在一所教学医院的心脏-风湿病诊所进行了一项观察性和横断面研究。该队列包括年龄在40-75岁，符合RA ACR/EULAR分类标准的患者，患者于2014年8月至2023年7月招募。心血管危险因素和合并症被定义为包括在患者医疗记录中的诊断或对这些疾病的治疗使用。结果纳入523例RA患者；大多数是女性（92.3%）。中位年龄为55岁（48.9-61.0岁）。最常见的心血管危险因素是超重（219人，42%）、肥胖（157人，32.0%）、血脂异常（165人，31.5%）和高血压（164人，31.3%）。我们还发现，12.1%未诊断为高血压的患者血压升高，17.2%报告高血糖，70.6%未诊断为2型糖尿病和血脂异常的患者分别出现脂质谱改变。结论类风湿关节炎患者存在心血管危险因素。超重、肥胖和血脂异常是我们队列中最常见的心血管危险因素。在先前未诊断为血脂异常的患者中，有一半报告了血脂谱的改变。

{"title":"Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic","authors":"Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza","doi":"10.1016/j.reumae.2025.501813","DOIUrl":"10.1016/j.reumae.2025.501813","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.</div></div><div><h3>Methods</h3><div>We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.</div></div><div><h3>Results</h3><div>523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.</div></div><div><h3>Conclusion</h3><div>Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501813"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis 轴性脊柱炎患者化脓性汗腺炎的患病率。

Reumatologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.reumae.2025.501808

Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura

Objectives

To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.

Patients and methods

We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.

Results

A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs 18%; p = 0.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs 3.2 ± 2.1; p = 0.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs 5.5 ± 3.5; p < 0.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs 27.8 ± 13.5 years; p = 0.001). No significant differences were found for the remaining variables studied.

Conclusion

This study suggests that prevalence of HS in patients with axSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.

目的：确定轴性脊柱炎（AxSpA）患者化脓性汗腺炎（HS）的患病率，并描述诊断为HS的患者的临床、实验室和影像学特征。患者和方法：我们对一家三级医院的265例AxSpA患者进行了一项横断面研究。使用问卷对患者进行HS筛查，随后由皮肤科医生进行诊断确认。我们收集了人口统计、临床、实验室和放射学数据。根据HS的诊断对患者进行分类。对两组进行描述性分析和比较。结果：265例患者中有148例（55.8%）完成了筛查问卷。9例（6.1%）患者筛查呈阳性，但仅有4例（2.7%）确诊为HS。研究期间确诊了3例患者，平均诊断延迟14.25年。所有患者均为轻度HS （Hurley期），当有HS和没有HS的患者进行比较时，HS组吸烟者较多(75% vs 18%；p = 0.005)，根据BASDAI，疾病活动性更高(5.6±2.3 vs 3.2±2.1；p = 0.026)，根据轴向BASRI(1.5±1.3 vs 5.5±3.5；结论：本研究提示axSpA患者HS患病率高于普通人群。这种关联的知识应该鼓励临床医生询问HS的症状，并积极寻找病变。

{"title":"Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis","authors":"Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura","doi":"10.1016/j.reumae.2025.501808","DOIUrl":"10.1016/j.reumae.2025.501808","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.</div></div><div><h3>Patients and methods</h3><div>We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.</div></div><div><h3>Results</h3><div>A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs 18%; p = 0.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs 3.2 ± 2.1; p = 0.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs 5.5 ± 3.5; p < 0.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs 27.8 ± 13.5 years; p = 0.001). No significant differences were found for the remaining variables studied.</div></div><div><h3>Conclusion</h3><div>This study suggests that prevalence of HS in patients with axSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501808"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling 利用细胞因子谱研究系统性红斑狼疮（SLE）和类风湿关节炎（RA）患者的潜在生物标志物和治疗靶点。

Reumatologia clinica

Pub Date : 2025-01-01 DOI: 10.1016/j.reumae.2025.101805

Akhil Akhil , Rohit Bansal , Jyotsana Kaushal , Aman Sharma , Archana Bhatnagar

Objectives

Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.

Methodology

Age and sex matched healthy donors and patients (n = 38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.

Results

A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.

Conclusion

This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.

目的：研究慢性自身免疫性疾病中细胞因子谱的复杂性具有重要的临床意义。为了解决SLE和RA相关的异同，有必要评估它们的细胞因子趋化因子谱。这样的分析将指出差异，从而导致探索细胞因子/趋化因子作为生物标志物的潜力。因此，这项研究是由理解这一水平的主要差异的概念驱动的，希望对诊断/治疗做出贡献。对系统性自身免疫性疾病（如SLE和RA）进行了一项多重研究，分析了40名分析者与健康对照者的比较。方法：招募年龄和性别匹配的健康供体和患者（n=38），采用Bio-plex多重免疫分析系统进行血浆细胞因子分析。结果：与健康志愿者的比较显示SLE和RA中各种趋化因子的差异改变。蛋白相互作用分析发现趋化因子的核心复合物（CXCL10、CCL5、CXCL12、CXCL9、CXCL1和CXCL27）是中心调节剂，表明它们具有作为生物标志物的潜力。使用DSigDB数据库进行药物预测，确定乙酰香草酮是对抗该核心复合物的潜在药物。在比较有或没有关节炎合并症的狼疮患者时，细胞因子水平升高：IL-12、SCF和TNF-a与狼疮患者的关节炎显著相关。TNF-a成为关节炎的潜在指标。结论：本研究增强了我们对细胞因子/趋化因子在这些系统性疾病中的复杂相互作用的理解，并表明它们作为检测靶点和诊断范例的用途。

{"title":"Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling","authors":"Akhil Akhil , Rohit Bansal , Jyotsana Kaushal , Aman Sharma , Archana Bhatnagar","doi":"10.1016/j.reumae.2025.101805","DOIUrl":"10.1016/j.reumae.2025.101805","url":null,"abstract":"<div><h3>Objectives</h3><div>Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.</div></div><div><h3>Methodology</h3><div>Age and sex matched healthy donors and patients (<em>n</em>  <!-->38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.</div></div><div><h3>Results</h3><div>A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.</div></div><div><h3>Conclusion</h3><div>This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101805"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0